HEK293/Human ASGR1 Stable Cell Line
描述（Description）
HEK293/Human ASGR1 Stable Cell Line
应用说明（Application）
Binding assay by FACS and cell based ELISA.
生长特性（Growth Properties）
Adherent
筛选标记（Selection Marker）
Hygromycin B (200 μg/mL)
培养基（Culture Medium）
DMEM medium + 10% FBS
冻存液（Freeze Medium）
10% DMSO + 90% FBS
装量（Quantity）
1 vial contains at least 5x10^6 cells in 1 ml of 10% DMSO in FBS.
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
背景（Background）
ASGPR, a transmembrane C-type lectin, recognizes a wide variety of ligands that contain either terminal galactose (Gal) or N-acetylgalactosamine (GalNAc) residues and has been identified as a highly selective receptor on hepatocytes. The ASGR is composed of both a major (ASGR1) and minor subunit (ASGR2). ASGR1 has been shown to be efficiently targeted to the plasma membrane and to undergo constitutive endocytosis and recycling and found mainly expressed in the human liver.
Permits & Restrictions
This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
关键字： ASGR1稳定细胞系;ASGR1稳定细胞株;ASGR1细胞系;ASGR1细胞株;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。